Trabectedin in myxoid liposarcomas (MLS): A long-term analysis of a single-institution series

Annals of Oncology

Volumn 20, Issue 8, 2009, Pages 1439-1444

  Grosso, Federica ^a   Sanfilippo, R ^a   Virdis, E ^a   Piovesan, C ^a   Collini, P ^a   Dileo, P ^a   Morosi, C ^a   Tercero, J C ^b   Jimeno, J ^b   D'Incalci, M ^c   Gronchi, A ^a   Pilotti, S ^a   Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PHARMAMAR S A   (Spain)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Liposarcoma; Myxoid liposarcoma; Round cell liposarcoma; Trabectedin

Indexed keywords

ANTHRACYCLINE; IFOSFAMIDE; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR; THIGH;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TETRAHYDROISOQUINOLINES; THIGH;

EID: 69449106265     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp004     Document Type: Article

References (28)

1. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study. Lancet Oncol 2007; 8: 595-602.
2. Fletcher CD, Unni K. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002.
3. Brennan MF, Singer S, Maki RG et al. Sarcomas of the soft tissues and bone. In DeVita V, Hellman S, Rosenberg S (eds): Cancer: Principles and Practice of Oncology, 7th edn. Philadelphia: Lippincott Williams & Wilkins 2005; 1581-1637.
4. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
5. Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: Disappointment or challenge? Curr Opin Oncol 2007; 19: 336-340.
6. Singer S, Demetri GD, Baldini EH, Fletcher CD. Management of soft-tissue sarcomas: An overview and update. Lancet Oncol 2000; 1: 75-85.
7. Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin Oncol 1997; 24: 572-579.
8. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22: 890-899.
9. Morgan JA, Le Cesne A, Chawla S et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcomas after failure of prior anthracyclines and ifosfamide. ASCO Annual Proceedings Pt 1. J Clin Oncol 2007; 25(18S): (Abstr 10060).
10. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584.
11. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22: 1480-1490.
12. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-5492.
13. Orvieto E, Furlanetto A, Laurino L, Dei Tos AP. Myxoid and round cell liposarcoma: A spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 2001; 18: 267-273.
14. Antonescu CR, Tschernyavsky SJ, Decuseara R et al. Prognostic impact of p53 status, TLS-CHOP fusion transcript structure, and histologic grade in myxoid liposarcoma. Clin Cancer Res 2000; 6: 2788-2793.
15. Spillane AJ, Fisher C, Thomas JM. Myxoid liposarcoma - the frequency and the natural history of nonpulmonary soft tissue metastases. Ann Surg Oncol 1999; 6: 389-394.
16. Fiore M, Grosso F, Lo Vullo S et al. Myxoid/round cell and pleomorphic liposarcomas: Prognostic factors and survival in a series of patients treated at a single institution. Cancer 2007; 109: 2522-2531.
17. Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006; 42: 1484-1490.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Kanoe H, Nakayama T, Hosaka T et al. Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of translin and topoisomerase II in the process of translocation. Oncogene 1999; 18: 721-729.
20. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001; 19: 1256-1265.
21. Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/ metastatic GIST. Ann Surg 2007; 245: 341-346.
22. Casali PG, Bertulli R, Fumagalli E et al. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. J Chemother 2004; 16: 55-58.
23. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338.
24. Choi H, Charnsangavej C, de Castro Faria S et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004; 183: 1619-1628.
25. Riggi N, Cironi L, Provero P et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 2006; 66: 7016-7023.
26. Dileo P, Grosso F, Casanova M et al. Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy. J Clin Oncol 2007; 25(18S): 10040; ASCO Annual Meeting Proceedings.
27. Grosso F, Jones R, Blay JY et al. Connective Tissue Oncology Society. In 13th Annual Meeting, Seattle, WA. 2007 (Abstr 900).
28. Grosso F, Forni C, Frapolli R et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. Clin Oncol 2007; 25(18S): 10000; ASCO Annual Meeting Proceedings.